204 related articles for article (PubMed ID: 36555129)
21. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
Sane R; Agarwal S; Mittapalli RK; Elmquist WF
J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
[TBL] [Abstract][Full Text] [Related]
22. Effects of P-gp and Bcrp as brain efflux transporters on the uptake of [
Jung KH; Oh SJ; Kang KJ; Han SJ; Nam KR; Park JA; Lee KC; Lee YJ; Choi JY
Synapse; 2019 Nov; 73(11):e22123. PubMed ID: 31269310
[TBL] [Abstract][Full Text] [Related]
23. Metabolomic Profiling and Drug Interaction Characterization Reveal Riboflavin As a Breast Cancer Resistance Protein-Specific Endogenous Biomarker That Demonstrates Prediction of Transporter Activity In Vivo.
Zhang Y; Shipkova PA; Warrack BM; Nelson DM; Wang L; Huo R; Chen J; Panfen E; Chen XQ; Fancher RM; Ruan Q; Christopher LJ; Xue Y; Sinz M; Shen H
Drug Metab Dispos; 2023 Jul; 51(7):851-861. PubMed ID: 37055191
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in the in vitro and in vivo methods to assess impact of P-glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition.
Chatterjee S; Deshpande AA; Shen H
Biopharm Drug Dispos; 2023 Feb; 44(1):7-25. PubMed ID: 36692150
[TBL] [Abstract][Full Text] [Related]
25. Maternal and Fetal Exposure to (-)-Δ
Chen X; Unadkat JD; Mao Q
Drug Metab Dispos; 2023 Mar; 51(3):269-275. PubMed ID: 36446608
[TBL] [Abstract][Full Text] [Related]
26. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier.
Eisenblätter T; Hüwel S; Galla HJ
Brain Res; 2003 May; 971(2):221-31. PubMed ID: 12706238
[TBL] [Abstract][Full Text] [Related]
27. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
Cisternino S; Mercier C; Bourasset F; Roux F; Scherrmann JM
Cancer Res; 2004 May; 64(9):3296-301. PubMed ID: 15126373
[TBL] [Abstract][Full Text] [Related]
28. Effect of GenX on P-Glycoprotein, Breast Cancer Resistance Protein, and Multidrug Resistance-Associated Protein 2 at the Blood-Brain Barrier.
Cannon RE; Richards AC; Trexler AW; Juberg CT; Sinha B; Knudsen GA; Birnbaum LS
Environ Health Perspect; 2020 Mar; 128(3):37002. PubMed ID: 32212926
[TBL] [Abstract][Full Text] [Related]
29. P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson's disease candidate drug FLZ across the physiological and PD pathological in vitro BBB models.
Liu Q; Hou J; Chen X; Liu G; Zhang D; Sun H; Zhang J
PLoS One; 2014; 9(7):e102442. PubMed ID: 25036090
[TBL] [Abstract][Full Text] [Related]
30. Impact of Zn
Zaremba A; Helm F; Fricker G
Mol Pharm; 2019 Jan; 16(1):305-317. PubMed ID: 30422662
[TBL] [Abstract][Full Text] [Related]
31. Central Nervous System Distribution of Panobinostat in Preclinical Models to Guide Dosing for Pediatric Brain Tumors.
Zhang W; Oh JH; Zhang W; Rathi S; Larson JD; Wechsler-Reya RJ; Sirianni RW; Elmquist WF
J Pharmacol Exp Ther; 2023 Dec; 387(3):315-327. PubMed ID: 37827699
[TBL] [Abstract][Full Text] [Related]
32. Glucocorticoids modulate multidrug resistance transporters in the first trimester human placenta.
Lye P; Bloise E; Nadeem L; Gibb W; Lye SJ; Matthews SG
J Cell Mol Med; 2018 Jul; 22(7):3652-3660. PubMed ID: 29691980
[TBL] [Abstract][Full Text] [Related]
33. Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance.
Agarwal S; Elmquist WF
Mol Pharm; 2012 Mar; 9(3):678-84. PubMed ID: 22335402
[TBL] [Abstract][Full Text] [Related]
34. Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.
Feng B; Doran AC; Di L; West MA; Osgood SM; Mancuso JY; Shaffer CL; Tremaine L; Liras J
J Pharm Sci; 2018 Aug; 107(8):2225-2235. PubMed ID: 29608887
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up.
Agarwal S; Hartz AM; Elmquist WF; Bauer B
Curr Pharm Des; 2011; 17(26):2793-802. PubMed ID: 21827403
[TBL] [Abstract][Full Text] [Related]
36. Localized Down-regulation of P-glycoprotein by Focused Ultrasound and Microbubbles induced Blood-Brain Barrier Disruption in Rat Brain.
Cho H; Lee HY; Han M; Choi JR; Ahn S; Lee T; Chang Y; Park J
Sci Rep; 2016 Aug; 6():31201. PubMed ID: 27510760
[TBL] [Abstract][Full Text] [Related]
37. ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS.
Daood M; Tsai C; Ahdab-Barmada M; Watchko JF
Neuropediatrics; 2008 Aug; 39(4):211-8. PubMed ID: 19165709
[TBL] [Abstract][Full Text] [Related]
38. Fetal glucocorticoid exposure leads to sex-specific changes in drug-transporter function at the blood-brain barrier in juvenile guinea pigs.
Eng ME; Bloise E; Matthews SG
FASEB J; 2022 Apr; 36(4):e22245. PubMed ID: 35262963
[TBL] [Abstract][Full Text] [Related]
39. A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration.
Gonçalves J; Silva S; Gouveia F; Bicker J; Falcão A; Alves G; Fortuna A
Int J Pharm; 2021 Jan; 593():120161. PubMed ID: 33307160
[TBL] [Abstract][Full Text] [Related]
40. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
